Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Nonpsychoactive, neuroprotective cannabinoids available for licensing from NIH

Jan. 7, 1999

Mayo Clinic closes in on gene causing PD and essential tremor

Jan. 5, 1999

Second phase II trial commences for SIB-1508Y

Jan. 5, 1999

CytoTherapeutics granted U.S. patent covering human neural stem cells

Jan. 5, 1999

Warner-Lambert claims new kappa-opioid agonists and their use

Jan. 4, 1999

Novel compounds synthesized at SmithKline Beecham act at several 5-HT receptor subtypes

Jan. 4, 1999

New treatment for AIDS-related pain progresses to clinical testing

Jan. 4, 1999

Novo Nordisk describes novel muscarinic cholinergic receptor modulators

Dec. 30, 1998

First U.S. marketing approval for Cephalon: Provigil cleared for narcolepsy-associated EDS

Dec. 29, 1998

YM-872: neuroprotective effects in animal model indicate potential in acute ischemic stroke

Dec. 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...